Dianthus Therapeutics to Present Claseprubart Data in CIDP and Myasthenia Gravis at AANEM 2026

Key Takeaways

• Dianthus Therapeutics will present claseprubart, an investigational complement inhibitor, in one oral and four poster presentations at the AANEM Annual Meeting, September 29 to October 2 in Orlando, Florida.
• The presentations cover chronic inflammatory demyelinating polyneuropathy (CIDP), with an interim analysis of the Phase 3 CAPTIVATE trial, and generalized myasthenia gravis (gMG), including data from the Phase 2 MaGic open-label extension.
• Investigators cite a 75% response rate in the interim responder analysis of the first 40 participants who completed unblinded Part A of CAPTIVATE. Claseprubart is not approved for any indication anywhere.

Dianthus Therapeutics, a clinical-stage biotechnology company focused on severe autoimmune diseases, announced five presentations of claseprubart data at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting.

Claseprubart is a monoclonal antibody that selectively targets the classical complement pathway by inhibiting only the active form of C1s, a clinically validated complement target. It uses YTE half-life extension technology, designed to allow a subcutaneous, infrequently dosed, self-administered injection. The company says that preserving the lectin and alternative pathways may lower the risk of infection from encapsulated bacteria. The FDA granted claseprubart Orphan Drug Designation for myasthenia gravis in May 2026.

The oral presentation covers the CAPTIVATE interim analysis, a pivotal Phase 3 study of claseprubart in CIDP, and will be delivered by Richard Lewis, MD, of Cedars-Sinai on October 1 from 1:21 to 1:29 p.m. ET as part of the Industry-Supported Research Highlights session. Lewis said the 75% response rate in the first 40 participants completing unblinded Part A came with consistent, clinically meaningful improvements across multiple measures of function and disability in a broad patient population with varied prior treatment experience. Jeffrey Allen, MD, will present the same analysis as a poster.

Three of the posters address gMG. Tuan Vu, MD, of the University of South Florida Morsani College of Medicine will present sustained safety and efficacy data at the MGFA Scientific Session on September 29 from 2:30 to 3:30 p.m. ET. Vu said the Phase 2 MaGic open-label extension showed sustained efficacy and a continued favorable safety profile. Said Beydoun, MD, will present a poster on minimal symptom expression with claseprubart. Vu will also present a poster on the potential mechanistic advantages of targeting upstream (aC1s) versus downstream complement blockade in myasthenia gravis. The CAPTIVATE poster and both of these posters will be shown on September 30 from 6:15 to 6:45 p.m. ET and again on October 1 from 2:45 to 3:15 p.m. ET. The presentations will be posted in the Scientific Publications section of the Dianthus website.